Compare eBay Inc (EBAY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Mesoblast Limited — how do they compare? eBay Inc trades at $111.53 (market cap $49.83B), while Mesoblast Limited trades at $14.1 (market cap $1.75B). The key difference: eBay Inc is far larger — about 28.5× Mesoblast Limited's market cap, and eBay Inc pays a 1.11% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold eBay Inc for 134 Days and Mesoblast Limited for 14 Days on average.
| EBAY | MESO | |
|---|---|---|
Market Cap | $49.83B | $1.75B |
Volume | 2,986,953 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $20.96 |
52-Week Low | $79.41 | $13.19 |
Typical Hold Time | 134 Days | 14 Days |
Enterprise Value | $53.65B | $1.83B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
eBay (EBAY) trades at $107.6, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $117.68 implying upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is steady, reaching $11.10B in 2025, supported by strong profitability margins including a net income margin of 18.57% and an impressive ROE of 47.38%.
The outlook is positive, driven by earnings momentum and strategic focus on collectibles and live commerce, but risks include competitive pressures from Amazon's new multi-platform tools and potential volatility from GameStop's significant stake. Investor sentiment is mixed, with nearly equal buy and hold ratings from analysts.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
